9.80

0.81% -0.0805

After Hours: 9.80

Daxor Corporation (DXR)

Overview News Price History Discussions Forecast Dividend History

Daxor Corporation stock is currently priced at $9.80, with a 24-hour trading volume of 5,056. It has seen a -0.81% decreased in the last 24 hours and a +10.11% rose in the past month. The chart indicates a potential bearish trend, as the stock is below the $9.87 pivot point. If it approaches the $9.80 support level, significant changes may occur.

Previous Close:

$9.8805

Open:

$9.71

24h Volume:

5,056

Market Cap:

$47.10M

Revenue:

$1.28M

Net Income/Loss:

$280.60K

P/E Ratio:

-122.50

EPS:

-0.08

Net Cash Flow:

1W Performance:

+1.55%

1M Performance:

+10.11%

6M Performance:

+22.81%

1Y Performance:

-13.58%

1D Range:

$9.51

$9.95

52W Range:

$7.11

$13.13

Daxor Corporation Stock (DXR) Company Profile

Name

Daxor Corporation

Sector

Healthcare (1213)

Industry

Medical Instruments & Supplies (60)

Phone

212-330-8500

Address

Empire State Building, Suite 7120 350 Fifth Avenue, New York, NY

Employee

Twitter

@DaxorBVA

Next Earnings Date

2024-03-22

Latest SEC Filings

DXR's Discussions on Twitter

Daxor Corporation Stock (DXR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-16-19	Initiated	Ascendiant Capital Markets	Buy

Daxor Corporation Stock (DXR) Latest News

Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital

GlobeNewswire Inc.

Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics

GlobeNewswire Inc.

Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024

GlobeNewswire Inc.

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

GlobeNewswire Inc.

Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure Patients

GlobeNewswire Inc.

Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference

GlobeNewswire Inc.

Daxor Corporation Stock (DXR) Financials Data

Daxor Corporation (DXR) Revenue 2024

DXR reported a revenue (TTM) of $1.28 million for the quarter ending December 31, 2023, a -78.00% decline year-over-year.

Daxor Corporation (DXR) Net Income 2024

DXR net income (TTM) was $280.60 thousand for the quarter ending December 31, 2023, a -94.09% decrease year-over-year.

Daxor Corporation (DXR) Earnings per Share 2024

DXR earnings per share (TTM) was -$0.7197 for the quarter ending December 31, 2023, a -161.51% decline year-over-year.

Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia. It also provides semen banking, blood storage, andrology, and general lab testing services. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was founded in 1970 and is headquartered in New York, New York.